In another patient with lung adenocarcinoma who was EGFR-positive and experienced disease progression on osimertinib, ctDNA showed a subclonal KRASG12C mutation that was not detected on prior tissue biopsy, consistent with acquired resistance to EGFR inhibitors, as previously demonstrated.21 Here, EGFR is linked to lung adenocarcinoma.